Clinical trials: Stage I Skin Cancer
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE
Breast Cancer
Effect of SBG in Patients With Breast Cancer
This study is set up to determine whether soluble beta-glucan (SBG) has unfavourable side effects beneficial treatment effects when given in combination with standard antibody and chemotherapy to patients with breast cancer.
- Trial name
- NCT00533364
- Testing
- SBG (Soluble beta-glucan)
- Where
- 2 sites in Norway
- Volunteers
- 11 people
- Sponsor
- Biotec Pharmacon ASA
Metastatic Breast Cancer
Clinical Trial of Comparative Study of GB221 Pharmacokinetics
The primary objective is to assess the safety of a single dose of GB221 compared to Herceptin® when administered as a single IV injection at a dose of 8 mg/kg.
- Trial name
- NCT04175171
- Testing
- Coprelotamab Injection, Trastuzumab Injection
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Genor Biopharma Co., Ltd.
Breast Cancer
BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00049244
- Testing
- capecitabine, ixabepilone
- Where
- United States
- Sponsor
- R-Pharm
Chemotherapy-induced Neutropenia
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer
The purpose of the present trial is to evaluate the safety, tolerability and pharmacokinetics(PK)/pharmacodynamics(PD) of single subcutaneous injection of GW003 in breast cancer patients.
- Trial name
- NCT02725606
- Testing
- Pegylated Recombinant Human G-CSF, GW003
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Breast Neoplasms
GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer
Primarily to evaluate the rates of clinical and radiological response in the 2 groups. Secondarily rate of histological response.
- Trial name
- NCT00617968
- Testing
- DOCETAXEL
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Sanofi
Breast Cancer, Advanced Solid Tumor
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
This is a Phase 1 dose escalation and dose expansion phase I study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of RGT-419B as monotherapy in Chinese patients with HR+/HER2…
- Trial name
- NCT06299124
- Testing
- RGT-419B
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Regor Pharmaceuticals Inc.
Melanoma
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
The purpose of this early (phase I/II) clinical trial is to assess the effects (both good and bad) of genetically modified T cells after chemotherapy on your cancer and general health.
- Trial name
- NCT01350401
- Testing
- Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Adaptimmune
Healthy Volunteers, Breast Cancer
Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients
Primary purpose of the clinical study is to evaluate the safety, biodistribution and radiation dosimetry of [131I]-SGMIB Anti-HER2 VHH1 in healthy volunteers and patients with HER2+ breast cancer.
- Trial name
- CAM-VHH1 (NCT02683083)
- Testing
- [131I]-SGMIB Anti-HER2 VHH1
- Where
- Belgium
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Precirix
Stage IV Melanoma
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
This study evaluates the effectiveness of adding a single four-day treatment of the fusion protein A-dmDT390-bisFv(UCHT1) - plus single palliative tumor radiation - with standard of care KEYTRUDA (Pembrolizumab) therapy for the…
- Trial name
- NCT02990416
- Testing
- A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Virogen Biotechnology Inc.
HER2-expressing Cancers
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable)…
- Trial name
- NCT02892123
- Testing
- ZW25 (Zanidatamab), Paclitaxel, Capecitabine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 279 people
- Sponsor
- Jazz Pharmaceuticals
Carcinoma, Breast
CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.
- Trial name
- NCT00043394
- Testing
- 0.04 mg/kg CpG 7909, Herceptin®, 0.08 mg/kg CpG 7909
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pfizer
Phase 1: Advanced or Refractory Solid Tumours, Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer
Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours
Liposomal formulations are frequently used today in the treatment of cancer. LiPlaCis is the first targeted liposomal formulation with a tumour triggered release mechanism to undergo clinical development in oncology and it is…
- Trial name
- LiPlaCis (NCT01861496)
- Testing
- LiPlaCis
- Where
- 4 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Allarity Therapeutics
Cutaneous T-Cell Lymphoma
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
The purpose of this trial is to determine the effect of HuMax-CD4 as a treatment for early stage cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00071071
- Testing
- HuMax-CD4
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genmab
Cervical Cancer, Genital Wart
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45…
- Conditions
- Cervical Cancer, Genital Wart, CIN1, CIN2
- Trial name
- NCT05584332
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- China
- Volunteers
- 3,131 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Oncology, MEK Mutation
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway…
- Conditions
- Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation
- Trial name
- NST-628 (NCT06326411)
- Testing
- NST-628
- Where
- 23 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- Nested Therapeutics, Inc
Breast Cancer
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
The current trial, BNIT-BR-003, will evaluate the safety and biological activity of a fixed dose of MVA-BN®-HER2 following adjuvant chemotherapy in patients with HER-2-positive breast cancer.
- Trial name
- NCT01152398
- Testing
- MVA-BN-HER2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bavarian Nordic
Actinic Keratosis
Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
This is an open-label, uncontrolled, non-randomised multi-centre trial in which 3 parallel groups will be enrolled. The trial includes three active treatment groups.
- Trial name
- NCT02124239
- Testing
- Ingenol mebutate
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- LEO Pharma
Malignant Melanoma
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
This study will determine the MDT of intravenous DTIC when administered in combination with a fixed dose of oral lenalidomide in subjects with metastatic malignant melanoma previously untreated with systemic chemotherapy.
- Trial name
- NCT00179608
- Testing
- CC-5013
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Celgene
Breast Cancer, Ovarian Cancer
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma
- Trial name
- NCT01831089
- Testing
- PM01183 + paclitaxel +/- bevacizumab
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 69 people
- Sponsor
- PharmaMar